GBT - GBT STOCK NEWS

Global Blood Therapeutics (GBT) granted 54,675 restricted stock units to eight new employees on December 1, 2020, under its Amended and Restated 2017 Inducement Equity Plan. This action complies with NASDAQ Listing Rule 5635(c)(4), offering inducements for new hires. GBT, founded in 2011, focuses on treatments for sickle cell disease (SCD) and has developed Oxbryta, the first FDA-approved therapy that inhibits sickle hemoglobin polymerization. The company is also advancing its pipeline with other promising candidates to further combat SCD.

Global Blood Therapeutics (GBT) announced the appointment of Dr. Kim Smith-Whitley as executive vice president and head of research and development, effective 2021. Dr. Smith-Whitley, a leading hematologist, brings over 30 years of experience in sickle cell disease (SCD) research and patient care. GBT aims to enhance efficiency and productivity in bringing innovative medicines to SCD patients. The company is focused on growth with a robust pipeline, including Oxbryta and inclacumab, to transform treatment for this condition.

Global Blood Therapeutics (GBT) announced new preclinical data on therapies targeting sickle cell disease (SCD) at the ASH Annual Meeting. Key highlights include the upcoming initiation of two pivotal Phase 3 trials for inclacumab, aimed at reducing vaso-occlusive crises (VOCs) and hospital readmissions. The trials are set to start in the first half of 2021. Additionally, promising data on GBT021601, a next-generation hemoglobin S polymerization inhibitor, was revealed, showcasing potential improvements in Hb levels and red blood cell health.

Global Blood Therapeutics (GBT) announced new data from the 72-week analyses of the Phase 3 HOPE Study of Oxbryta^® (voxelotor) for sickle cell disease (SCD). The findings, presented at the 62nd American Society of Hematology Annual Meeting, confirmed durable improvements in hemoglobin levels, with approximately 90% of patients achieving a hemoglobin rise of greater than 1 g/dL. Real-world studies echoed these results, highlighting significant improvements in overall health status. Oxbryta, approved in late 2019, shows the potential to mitigate complications associated with SCD.

Global Blood Therapeutics (GBT) has initiated an early access program for voxelotor in Europe and other regions for treating hemolytic anemia in sickle cell disease (SCD) patients aged 12 and older. The program addresses the significant unmet medical need for therapies outside the U.S. voxelotor, a first-in-class oral therapy, inhibits hemoglobin polymerization, treating the root cause of SCD-related anemia. GBT plans to seek regulatory approval for voxelotor across Europe to expand its availability.

Global Blood Therapeutics (GBT) announced participation in two virtual investor conferences. The events include the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2 at 2:30 p.m. ET and the Evercore ISI 3rd Annual HealthCONx on December 3 at 10:55 a.m. ET. Both fireside chats will be streamed live on GBT's website, with replays available for a month post-event. GBT is focused on developing treatments for sickle cell disease, having launched Oxbryta, the first FDA-approved treatment targeting the disease's root cause.

Global Blood Therapeutics (GBT) will engage in a virtual fireside chat at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 2:00 p.m. ET. The event will be accessible via live webcast on GBT’s website, with an archived replay available for a month post-event.

GBT focuses on developing treatments for sickle cell disease, having launched Oxbryta (voxelotor), the first FDA-approved treatment of its kind, and is advancing pipeline programs targeting pain crises and hemoglobin S polymerization.

Global Blood Therapeutics (GBT) announced on November 1, 2020, that its compensation committee granted options to 10 new employees for a total of 19,500 shares of common stock at an exercise price of $52.88. Additionally, restricted stock units for 89,675 shares were awarded under the Amended and Restated 2017 Inducement Equity Plan. These grants comply with NASDAQ Listing Rule 5635(c)(4) and are aimed at incentivizing new hires to join the company, enhancing its efforts in treating sickle cell disease.

Global Blood Therapeutics (GBT) reported Q3 2020 net revenues of $36.9 million from Oxbryta (voxelotor), increasing total revenues for the first nine months to $82.5 million. The company recorded over 1,000 new prescriptions despite rising COVID-19 cases. GBT secured 90% reimbursement coverage ahead of schedule and established a distribution agreement for Oxbryta in the Gulf Cooperation Council. The net loss narrowed to $59.9 million from $64.5 million in Q3 2019. GBT expects increased operating costs in future quarters due to commercialization efforts.